[1]
M. Taniwaki, M. Yoshida, Y. Matsumoto, K. Shimura, J. Kuroda, and H. Kaneko, “ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING”, Mediterr J Hematol Infect Dis, vol. 10, no. 1, p. e2018014, Feb. 2018.